RSS
1 Oct 2019

Positive Interactions With EMA Provide Route to Conditional Marketing Authorization of Lead Candidate Nefecon

Author: admintech | Filed under: Press Release

STOCKHOLM, Oct. 1, 2019 /PRNewswire/ — Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, currently in…

This entry was posted on Tuesday, October 1st, 2019 at 1:40 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»